Introduction
============

Current interest in soy foods is largely driven by documented research on the potential health benefits of phytoestrogens ([@b15-cia-3-711]; [@b2-cia-3-711]; [@b10-cia-3-711]). Soybeans are a staple of the Asian diet ([@b14-cia-3-711]). The main isoflavone exposure is 17.7 mg total isoflavones (IF) per day in China (Lui et al 2004) and 47.2 mg per day total IF in Japan ([@b3-cia-3-711]). In contrast, the estimated mean dietary daily IF intake reported for the UK was calculated to be 0.8 mg ([@b9-cia-3-711]). The average consumption of phytoestrogens in Europe is estimated to be less than 2 mg/day ([@b5-cia-3-711]; [@b23-cia-3-711]). Consequently, an increase in soy consumption in Western countries could be a promising innovative target. A positive relationship has been demonstrated between the level of soy consumption and bone mineral density ([@b16-cia-3-711]). However, what is critical to biological efficacy of these compounds is a thorough understanding of their bioavailability from different soya foods ([@b7-cia-3-711]). Indeed, the composition of the IF glucoside conjugates, which is altered during the industrial processing and cooking (Coward et al 1998), should modify the rate of absorption and possibly the degree of further metabolism.

Futhermore, the variability of IF bioavailability can also be due to inter-individual differences in IF metabolism ([@b18-cia-3-711]). As a matter of fact, only 20%--35% of the adult population is able to convert daidzein into equol after ingesting soy or soy derivative products ([@b19-cia-3-711]). This conversion is carried out by the intestinal bacteria ([@b22-cia-3-711]; [@b4-cia-3-711]). These inter-individual differences could, at least, partially explain the differences in the biological effects observed following soy consumption. In a 2-year study carried out in post-menopausal women who drank 500 ml of soymilk either with or without IF, greater effects on bone health were elicited when volunteers were able to produce equol ([@b12-cia-3-711]).

This study is the first step of an interventional multicenter trial which aimed to study the potential preventive effect of soy IF on bone mass in postmenopausal women (PHYTOS shared-cost European RTD program: the prevention of osteoporosis by nutritional phytoestrogens, QLK1-CT2000-00431). The purpose of this work package was to set up a pilot trial to improve compliance of IF in two IF-enriched foods providing the same IF circulating levels in postmenopausal women.

Materials and methods
=====================

Study design
------------

The study was a randomized, crossover, parallel multicenter trial conducted in the Netherlands (TNO Quality of Life, Zeist), Italy (INRAN, Rome), and France (INRA, Clermont-Ferrand). The protocol of this study was approved by the ethical committee in each country (the independent Medical Ethics Committee of TNO for the Netherlands, The Medical Ethics Committee of the University of Rome "La Sapienza" for Italy and the "Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale" for France).

Subjects were healthy Caucasian females selected via a phone questionnaire. All the volunteers gave their written informed consent. In each country, 14 healthy ambulatory postmenopausal women, less than five years and menstrual bleeding within 12 months, (mean age: 53.28, range from 49 to 60 years; mean age at menopause: 50.78 years) were recruited and completed the study. Subjects had a body mass index (BMI) ranging from 20 to 29 kg/m^2^. Subjects were randomly allocated to two group with BMI, age and time since last menses as randomization variables.

Subjects osteoporotic, with severe scoliosis, with a history of medical or surgical events that might significantly affect the study outcome, or who were using a concomitant medication known to affect bone metabolism were excluded. Interfering habits such as strict vegetarian and vegan, high fiber and high soy diets, allergy for soy, and frequent alcohol consumption (\>2 drinks/day, \>15 drinks/week) were considered as exclusion criteria, as well. Participants were willing to take soy-enriched products, had not been involved in any clinical trial six months before entering this study and, were not in the exclusion period of the national index of healthy volunteers.

Volunteers underwent a screening visit that included a health history questionnaire, a physical examination and routine blood chemistry. The nutrition history questionnaire was used to investigate usual dietary intake patterns.

During the whole study (18 days), volunteers were requested to consume their habitual diet, although they were given detailed dietary instructions to minimize prebiotics-containing food products or to avoid phytoestrogen consumption. Subjects were assigned to one of two groups (seven women each). Two different IF-enriched foods were provided to the volunteers: biscuits (Danone Vitapole, Palaiseau France) and cereals bars (Nutrition Santé, Revel, France). They both were designed to bring 100 mg IF aglycones in two servings (60%--75% genistein; 23%--35% daidzein; 1%--5% glycitin; 83.5 mg IF glycosyled; Prevastein^®^HC, Eridania Beghin-Say, Vilvoorde, Belgium). The composition is given in [Table 1](#t1-cia-3-711){ref-type="table"}. The first group of volunteers had to eat, including meals, two IF-enriched biscuits daily for three days (D1--D3). After a wash-out period of 11 days (D4--D14), under the same conditions they were provided two IF-enriched cereal bars for three days (D15--D18). The second group started with the cereal bars and received the biscuits during the second period ([Figure 1](#f1-cia-3-711){ref-type="fig"}).

Compliance with consumption was monitored by a combination of specially designed forms and return of unconsumed foods throughout the study and the assessment of plasma and urinary IF concentrations at four time points.

Sample size calculation
-----------------------

The sample size has been calculated to detect differences in plasma levels of total IF between groups consuming different food matrixes equal to ½ SD (0.15 μmol/L) observed in 12 adult women after a single dose of 126 mg IF administered as soy milk ([@b26-cia-3-711]). A total of 42 subjects (14 per country) is required to detect differences between groups with 80% power, significance level set at 0.05, and assuming a 20% drop-out rate.

Blood and urine collection
--------------------------

At days 1, 4, 15, and 18, 7 ml of blood were collected by venous puncture, ie, a total volume of 28 ml. The volunteers were asked to fast since their dinner on the previous day. Venous blood samples were drawn on heparin tubes subjected to centrifugation (2000 g × 10 min at 4 °C). Then plasma was aliquoted and frozen (−80 °C) for genistein and daidzein analysis and one was archived.

Subjects were also required to complete a 24-h urine samples collection before each visit (from 7am the previous day to 7am the visit day) on days 1, 4, 15, and 18 and brought back the fl ask. The volume of each 24-h urine sample was measured, and subsamples were taken, adding 0.1% ascorbic acid and frozen (−20 °C) until genistein, daidzein, equol and O-DMA analysis. One aliquot was archived.

Isoflavone assessment
---------------------

Genistein and daidzein were analyzed, in duplicate in plasma, by RIA (TR-FIA), using as internal standard tritiated estradiol beta-glucuronide. The sensitivity limit of the method is 1.8 pg/μl, 0.35 nM, being recovery calculated after hydrolysis and extraction.

Genistein, daizein, equol and O-DMA were analyzed in duplicate in urine sample by GC/SIM, using deuterium labeled internal standards. In this method, isoflavonoids were hydrolyzed and measured as free aglycones. This newly-developed immunoassay for IF was compared with GC/MS and HPLC methods to ensure adequate performance in terms of their precision, specificity and spiking/recovery of added synthetic isoflavones ([@b1-cia-3-711]).

Statistics
----------

The data are expressed as individual values and means ± standard error of the mean (SEM). Statistical tests have been chosen according to the data distribution (Kolmorogov--Smirnov test). For each group a comparison was established between results at the first experimental day and after three days of consumption. Analysis of variance (ANOVA) was used to test for any significant difference among groups. These tests were carried out under Statview software (Microsoft, San Diego, CA, USA). A two-way ANOVA was performed, one way for the country and the other way for the treatment. When ANOVA was significant the Student's T-test was used.

Results
=======

Effect of food matrix on isoflavones bioavailability
----------------------------------------------------

In France, urinary and plasma levels of genistein and daidzein followed the same pattern, ie, an increase at day 4 and 18 ([Figure 2](#f2-cia-3-711){ref-type="fig"}). Basal plasma genistein levels at day 1 were not significantly different from those measured at the beginning of the second experimental period (day 15). Daidzein concentrations followed the same pattern. Consequently, the wash-out period was efficient. Whatever the IF consumption period, plasma concentrations increased after 3 days and values reached similar levels at day 4 and day 18.

Urinary levels of genistein and daidzein followed the same pattern than in plasma, ie, an increase at day 4 and 18, concentrations at the beginning of each experimental period being similar. Equol or O-DMA excretion exhibited same behavior than genistein or daidzein.

The two food matrix did not have any influence on equol productions, as shown by the number of equol producers and non producers ([Figure 3](#f3-cia-3-711){ref-type="fig"}).

Isoflavones bioavailability in each country
-------------------------------------------

Whatever the period, plasma genistein levels did not differ among volunteers in each center. The highest basal levels of daidzein were measured in Netherlands and being even lower in France than in Italy. After three days of IF consumption, daidzein values were similar in all three countries except at day 4 in Italy.

In Netherlands, genistein urinary excretion was lower (p \< 0.05) than in France and in Italy at day 4 and 18. Daidzein urinary excretion was lower (p \< 0.05) than those in Italy ([Figure 4](#f4-cia-3-711){ref-type="fig"}).

Average equol excretion rate (nmol/24 h) was much lower in the Netherlands than in the other countries (France: 5212 ± 1268; Italy: 3218 ± 1268). In the Netherlands, only 28.6% of the volunteers were considered as high equol producers (\> 1000 nmol/24 h), against 57% in France and the average urinary production among those producers (nmol/24 h) was much lower than in the other countries ([Table 2](#t2-cia-3-711){ref-type="table"}).

Discussion
==========

Following soy food consumption, IF are biotransformed by intestinal microflora, a required step for absorption. IF are hydrolyzed by glucosidases to the aglycones daidzein, genistein and glycitein. Some are further metabolized to compounds such as equol, dihydrodaidzein and p-ethylphenol. Equol is more estrogenic than its precursors, whereas, p-ethylphenol is nonestrogenic. Daidzein is formed from formononetin and is metabolized into equol and O-DMA. Genistein is formed from biochanin A and metabolised to p-ethylphenol. Elimination of IF is predominantly via the urine (mainly equol), although total recovery by mass balance is less than 50%, suggesting that unrecognized metabolites are being formed. Only some pharmacokinetic studies have been conducted in which isoflavones were measured in human subjects simultaneously in plasma urine and feces ([@b26-cia-3-711]). [@b8-cia-3-711] determined the metabolites O-DMA and equol, in addition to genistein and daidzein in urine after intake of fermented and unfermented soy foods, but no analysis was performed in blood.

In the present study, IF plasma levels would reach a plateau after three days of IF-enriched food consumption and would return to baseline after a wash-out period of one week. A significant increase in both plasma and urinary IF was shown after three days of consumption and concentrations returned to basal level in 15 days (wash-out period). This pattern was demonstrated to be similar in each of the three countries. According to data at the time the experiment started, elimination half-lifes of genistein and daidzein were considered to be short: 8 to 10 h and 6 to 8 h for genistein and daidzein, respectively. Moreover, several studies demonstrated entero-hepatic recirculation phenomena which lead to rather higher parameters up to 20 h for both IF ([@b17-cia-3-711]; [@b24-cia-3-711]).

In the present study plasma level reached quite high levels after consumption of IF-enriched biscuits or IF-enriched bars (nmol/l magnitude). In addition, because Prevastein contains more genistein (167 mg IF glycosyled/day composed of 100--125 mg genistein, 42--58 mg daidzein and 1.67--8.35 mg glycitin), the higher genistein concentrations than daizein make sense. In each country, daidzein concentrations in plasma were lower than those of genistein which reflect the ingested proportions and the reverse was observed in the urine samples. This is in accordance with previous studies undertaken on humans and rats ([@b20-cia-3-711]; [@b13-cia-3-711]) showing that daidzein excretion is higher than that of genistein. This phenomenon reflects a greater bioavailability of daidzein.

Several investigators have reported that individual variability in colonic microflora plays an important role in determining the preferred pathways of isoflavones metabolism and the bioavailability of isoflavones. There is variation in the ability of the bacteria to produce equol, about 30%--50% of the adult population does not excrete this bacterial metabolite in urine, when challenged daily with soy foods (Lampe et al 1998; Rowland et al 1999). In the early studies, it was found that two third of adults who consumed soy containing foods converted daidzein to equol ([@b22-cia-3-711]). This ability to converted daidzein into equol led to use of the term "converters" to describe persons who have the necessary bacterial enzymes or intestinal conditions to make this biotransformation ([@b21-cia-3-711]). In the present study, we have shown a significant difference in the ratio for equol producers in the three countries. IF was classified in three groups; according to the magnitude of production: high, medium and very low, French volunteers had the most important percentage of high equol producers (42%), in opposite to Italy (30%) or the Netherlands (21%). The very low producers were much numerous in The Netherlands and as volunteers exhibited quite important individual variations in basal plasma IF (including genistein and daidzein). Consequently, it can be hypothesized that country differences may be explained by dietary factors. This trend will have to be checked in the main trial on more postmenopausal women.

In this project, a difference in composition of product, in particular in fiber level (6.6 g/100 g of biscuits vs 3.4 g/100 g of bars) would have been modified the bioavailability of IF. Indeed, it has been established that concurrent dietary intake, in particularly fibers, may exert a major influence on isoflavones metabolism, by modulating intestinal microflora ([@b25-cia-3-711]). However, the level of IF did not appear to be altered by food matrix.

In conclusion, because the food matrix of biscuit or cereal bar does not modify IF metabolism, volunteers in the main intervention trial will have a choice between the biscuit or cereal bar.
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![Effect of isoflavones-enriched biscuits ( ![](cia-3-711f5.jpg)) or isoflavones-enriched cereal bars (□) consumption for 3 days (day 1 to day 4 and day 15 to day 18) on plasma genistein and daidzein levels, and urinary genistein, daidzein, equol and O-DMA concentrations. Values are expressed as means ± their standard errors (values for each country have been plotted together). Means values were all significantly different from day 1 or day 15.](cia-3-711f2){#f2-cia-3-711}

![Effect isoflavones-enriched biscuits (b) or isoflavones-enriched cereal bars (c) consumption for 3 days (day 15 to day 18) on urinary equol excreation at day 18. Individual values are given in each country (the Netherlands (□), France (▧) and italy ( ![](cia-3-711f5.jpg)), values above the dotted line (at 1000 nmol/24 h) were harvested in volunteers considered as high producers.](cia-3-711f3){#f3-cia-3-711}

![Effect of isoflavones-enriched food consumption for three days (day 1 to day 4 and day 15 to day 18) on plasma genistein and daidzein levels, and urinary genistein, daidzein, equol and O-DMA concentrations in the Netherlands (□), France (▧) and Italy ( ![](cia-3-711f5.jpg)).\
**Notes:** Values are expressed as means ± their standard errors. Values for both biscuits and cereal bars have been plotted together. Means values were all significantly different from day 1 or day 15. ^a^p \< 0.05 vs concentrations in France; ^\*^p \< 0.05 vs concentrations in The Netherlands, ^+^p \< 0.05 vs concentrations in Italy.](cia-3-711f4){#f4-cia-3-711}

###### 

Composition of the investigational products per 100 g of product[1](#tfn1-cia-3-711){ref-type="table-fn"}

  Nutritional analysis               Biscuits   Bars
  ---------------------------------- ---------- ------
  Energy (Kj)                        1846       1600
  Moisture (g)                       2.6        8.6
  Protein (g)                        6.6        6.0
  Carbohydrates (g)                  64.3       77.9
   Sugars (g)                        26.3       24.1
  Fat (g)                            17.3       4.4
   Saturated fatty acids (g)         4.3        2.2
   Monounsaturated fatty acids (g)   8.9        0.2
   Polyunsaturated fatty acids (g)   4.0        1.5
  Fibers (g)                         6.6        1.7
  Isoflavones aglycones (mg)         444        254
  Minerals                                      
   Calcium (mg)                      21         15
   Magnesium (mg)                    36         40
   Phosphorus (mg)                   131        103
   Iron (mg)                         1.22       1.03

**Note:** The subjects received combinations of the products equalling 24 g/d biscuits or 12 g/d bars.

###### 

Ability to produce equol in The Netherlands, France and Italy

                                                     The Netherlands                                       France        Italy
  -------------------------------------------------- ----------------------------------------------------- ------------- -------------
  Non equol producers (\<500 nmol/24 h)              64.3%                                                 28.6%         53.8%
  Low equol producers (\>500 nmol/24 h)              7%                                                    14%           15.4%
  High equol producers (\>1000 nmol/24 h)            28.6%                                                 57%           30.8%
  Average production in high producers (nmol/24 h)   2401 ± 841[a](#tfn2-cia-3-711){ref-type="table-fn"}   8906 ± 1765   7671 ± 1933

**Note:** p \< 0.05 *vs* values in France or Italy.
